Kaken Pharmaceutical Co Ltd (4521)

Tokyo

Currency in JPY

3,867.0

-14.0(-0.36%)

Closed·07:30:29

Fair Value

Unlock Value

Day's Range

3,864.0

3,923.0

52 wk Range

3,651.0

4,901.0

4521 Income Statement

Featured here, the Income Statement (earnings report) for Kaken Pharmaceutical Co Ltd, showing the company's financial performance from operating and non operating activities such as revenue, expenses and income for the last 4 periods (either quarterly or annually).

Period Ending:

2016

31/03

2017

31/03

2018

31/03

2019

31/03

2020

31/03

2021

31/03

2022

31/03

2023

31/03

2024

31/03

2025

31/03

Total Revenues

aa.aa

74,979

76,034

72,984

72,044

94,035

Total Revenues Growth

aa.aa

-15.97%

+1.41%

-4.01%

-1.29%

+30.52%

Cost Of Revenues

aa.aa

34,073

34,458

33,428

33,505

35,502

Gross Profit

aa.aa

40,906

41,576

39,556

38,539

58,533

Gross Profit Growth

aa.aa

-18.97%

+1.64%

-4.86%

-2.57%

+51.88%

Gross Profit Margin %

aa.aa

54.56%

54.68%

54.2%

53.49%

62.25%

Other Operating Expenses, Total

aa.aa

23,118

24,511

31,556

29,025

37,497

	Other Operating Expenses, Total Growth
	R&D Expenses
	Selling General & Admin Expenses
	Other Operating Expenses

aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	-3.55%	+6.03%	+28.74%	-8.02%	+29.19%
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	6,736	8,420	15,789	12,543	18,725
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	16,155	15,833	15,476	16,165	18,501
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	-	-	-	-	-

Operating Income

aa.aa

17,788

17,065

8,000

9,514

21,036

Operating Income Growth

aa.aa

-32.91%

-4.06%

-53.12%

+18.93%

+121.11%

EBIT Margin %

aa.aa

23.72%

22.44%

10.96%

13.21%

22.37%

Net Interest Expenses

aa.aa

376

379

421

462

585

Net Interest Expenses Growth

aa.aa

+0.27%

+0.8%

+11.08%

+9.74%

+26.62%

Interest Expense, Total

aa.aa

-17

-28

Interest And Investment Income

aa.aa

393

396

438

479

613

Other Non Operating Expenses, Total

aa.aa

306

-27

-342

EBT, Excl. Unusual Items

aa.aa

18,221

17,542

8,727

9,949

21,279

Gain (Loss) On Sale Of Assets

aa.aa

379

195

Other Unusual Items, Total

aa.aa

-58

-3,853

-1,912

-167

-1,557

EBT, Incl. Unusual Items

aa.aa

18,657

13,885

6,817

9,795

19,435

EBT, Incl. Unusual Items Growth

aa.aa

-29.84%

-25.58%

-50.9%

+43.68%

+98.42%

EBT, Incl. Unusual Items Margin

aa.aa

24.88%

18.26%

9.34%

13.6%

20.67%

Income Tax Expense

aa.aa

5,252

4,336

1,377

1,770

5,490

Net Income to Company

aa.aa

13,405

9,549

5,440

8,025

13,945

Minority Interest

aa.aa

Net Income

aa.aa

13,405

9,549

5,440

8,025

13,945

Net Income Growth

aa.aa

-30.8%

-28.77%

-43.03%

+47.52%

+73.77%

Net Income Margin %

aa.aa

17.88%

12.56%

7.45%

11.14%

14.83%

Preferred Dividend and Other Adjustments

aa.aa

Net Income to Common Excl. Extra Items

aa.aa

13,405

9,549

5,440

8,025

13,945

Basic EPS - Continuing Operations

aa.aa

347.37

251.44

144.79

212.66

365.42

Basic EPS - Continuing Operations Growth

aa.aa

-29.81%

-27.62%

-42.41%

+46.87%

+71.83%

Diluted EPS - Continuing Operations

aa.aa

347.37

251.44

144.79

212.66

365.42

Diluted EPS - Continuing Operations Growth

aa.aa

-29.81%

-27.62%

-42.41%

+46.87%

+71.83%

Basic Weighted Average Shares Outstanding

aa.aa

38.59

37.98

37.57

37.74

38.16

Diluted Weighted Average Shares Outstanding

aa.aa

38.59

37.98

37.57

37.74

38.16

Dividend Per Share

aa.aa

150

Dividend Per Share Growth

aa.aa

EBITDA

aa.aa

20,106

19,551

10,568

12,267

23,590

EBITDA Growth

aa.aa

-31.32%

-2.76%

-45.95%

+16.08%

+92.3%

EBITDA Margin %

aa.aa

26.82%

25.71%

14.48%

17.03%

25.09%

EBIT

aa.aa

17,788

17,065

8,000

9,514

21,036

* In Millions of JPY (except for per share items)

NSE 30

5,328.61

-1.12

-0.02%

NSE All Share

146,055.88

+107.40

+0.07%

US 30

44,444.30

+468.4

+1.07%

US 500

6,432.80

+59.3

+0.93%

FTSE 100

9,147.81

+18.10

+0.20%

DAX

24,050.12

-31.22

-0.13%

South Africa Top 40

93,808.58

+525.91

+0.56%

Market Movers

Name	Last	Chg. %	Vol.
Access Holdings	27.55	-0.54%	61.09M
Zenith Bank	74.00	0.00%	27.39M
Nigerian Breweries	74.40	0.00%	27.12M
Guaranty Trust Holding	99.00	-0.85%	26.50M
UBA	48.70	+1.25%	17.85M
Dangote Cement	577.00	0.00%	4.44M
Aradel Holdings	520.00	0.00%	1.89M

Name	Last	Chg. %	Vol.
Prestige	2.20	+10.00%	7.86M
Champion Brew	17.38	+10.00%	6.86M
Mansard Ins	17.710	+10.00%	4.73M
Sunu Assurances	6.05	+10.00%	13.54M
Abctrans	4.95	+10.00%	1.49M
Initiates	14.52	+10.00%	4.88M
Ellah Lakes	16.06	+10.00%	26.26M

Name	Last	Chg. %	Vol.
Juli	9.00	-10.00%	101.69K
Unilever Nigeria	71.30	-9.97%	4.19M
Custodian Allied	37.90	-9.55%	1.87M
Academy Press	8.30	-7.78%	1.07M
Maybaker	18.000	-7.69%	1.69M
Wema Bank	21.75	-6.05%	3.91M
Livestock	8.45	-5.06%	4.09M

Trending Stocks

Name	Last	Chg. %	Vol.
Aiico	4.23	+9.87%	64.99M
Linkassure	2.48	+9.73%	11.77M
Access Holdings	27.55	-0.54%	61.09M
Ellah Lakes	16.06	+10.00%	26.26M
Wema Bank	21.75	-6.05%	3.91M

Most Undervalued Stocks

Name	Last	Upside	Fair Value
A A Aa A	5,450.00	+42.64%	7,773.88
Aaaa Aaaaaaaaa	577.00	+40.93%	813.17
Aaaa Aaaaa	1,890.00	+34.32%	2,538.65
Aaaaaa Aaaaaaaaaaa	71.00	+26.96%	90.14
Aaaaaa	168.60	+26.01%	212.45
A Aaaaaaaaaaaaaaa	640.00	+16.86%	747.90

Name	Last	Upside	Fair Value
A A Aa A	5,450.00	+42.64%	7,773.88
Aaaa Aaaaaaaaa	577.00	+40.93%	813.17
Aaaa Aaaaa	1,890.00	+34.32%	2,538.65
Aaaaaa Aaaaaaaaaaa	71.00	+26.96%	90.14
Aaaaaa	168.60	+26.01%	212.45
A Aaaaaaaaaaaaaaa	640.00	+16.86%	747.90

See full list

Install Our AppScan QR code to install app

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers

Popular Searches

Please try another search

Kaken Pharmaceutical Co Ltd (4521)

4521 Income Statement

Trending Stocks